Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma

Despite novel therapies for melanoma, drug resistance remains a significant hurdle to achieving optimal responses. NRAS‐mutant melanoma is an archetype of therapeutic challenges in the field, which we used to test drug combinations to avert drug resistance. We show that BET proteins are overexpresse...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EMBO Mol Med
Main Authors: Echevarría‐Vargas, Ileabett M, Reyes‐Uribe, Patricia I, Guterres, Adam N, Yin, Xiangfan, Kossenkov, Andrew V, Liu, Qin, Zhang, Gao, Krepler, Clemens, Cheng, Chaoran, Wei, Zhi, Somasundaram, Rajasekharan, Karakousis, Giorgos, Xu, Wei, Morrissette, Jennifer JD, Lu, Yiling, Mills, Gordon B, Sullivan, Ryan J, Benchun, Miao, Frederick, Dennie T, Boland, Genevieve, Flaherty, Keith T, Weeraratna, Ashani T, Herlyn, Meenhard, Amaravadi, Ravi, Schuchter, Lynn M, Burd, Christin E, Aplin, Andrew E, Xu, Xiaowei, Villanueva, Jessie
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5938620/
https://ncbi.nlm.nih.gov/pubmed/29650805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201708446
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados